SCHEMBL6769338

SCHEMBL6769338

COc1cc2oc3ccccc3c2cc1NCc1cccc(OC)c1OC

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.58
ALDH1A1 P00352 10/20 0.57
KDM4E B2RXH2 9/20 0.57
MAPT P10636 9/20 0.57
HPGD P15428 8/20 0.57
KMT2A Q03164 8/20 0.57
MEN1 O00255 7/20 0.57
LMNA P02545 5/20 0.57
GAA P10253 3/20 0.57
HSD17B10 Q99714 2/20 0.57
ALOX15 P16050 1/20 0.57
RAB9A P51151 1/20 0.57
NPSR1 Q6W5P4 2/20 0.56
CYP1A2 P05177 2/20 0.56
CYP2C9 P11712 2/20 0.56
CYP2C19 P33261 2/20 0.56
CYP3A4 P08684 1/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
TDP1 Q9NUW8 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6483874 0.91 HPGD (0.63) ACHEALDH1A1KDM4EMAPTHPGD
SCHEMBL6485628 0.86 MAPT (0.56) ACHEALDH1A1KDM4EMAPTHPGD
SCHEMBL6481798 0.84 HDAC8 (0.57) ACHEALDH1A1KDM4EMAPTHPGD
SCHEMBL6774357 0.82 ALDH1A1 (0.56) ACHEALDH1A1KDM4EMAPTHPGD
SCHEMBL6765385 0.75 MAPT (0.61) ALDH1A1KDM4EMAPTHPGDKMT2A
SCHEMBL6484427 0.75 HDAC8 (0.57) ACHEALDH1A1KDM4EMAPTHPGD
SCHEMBL6483711 0.75 KDM4E (0.55) ACHEALDH1A1KDM4EMAPTHPGD
SCHEMBL12542220 0.74 MAPT (0.70) ACHEALDH1A1KDM4EMAPTHPGD
SCHEMBL7503353 0.73 ALDH1A1 (0.60) ALDH1A1KDM4EMAPTHPGDKMT2A
SCHEMBL7495432 0.72 ALDH1A1 (0.58) ALDH1A1KDM4EMAPTHPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 US claimed
US-6800656-B2 Tricyclic compounds and method of treating herpes virus WARNER LAMBERT COMPANY 2004-10-05 US disclosed
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 US disclosed
EP-1248777-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2002-10-16 EP disclosed
WO-2001051479-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2001-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus HDAC8, ZC3HAV1, ZCCHC8 ACHE 1631/4885ALDH1A1 4486/4885KDM4E 1279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.